TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Brief Summary: This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.


Options:
A: Arm Label: Treatment arm; Type: EXPERIMENTAL; Interventions: Drug: XAV-19 | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: XAV-19; Assigned to Arm(s): Treatment arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo arm
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Biological: Convalescent anti-SARS-CoV-2 MBT plasma | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control Group | Intervention Type: BIOLOGICAL; Name: Convalescent anti-SARS-CoV-2 MBT plasma; Assigned to Arm(s): Experimental group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
C: Arm Label: High-titer anti-influenza plasma; Type: EXPERIMENTAL; Interventions: Biological: High-titer anti-influenza plasma | Arm Label: Low-titer anti-influenza plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Low-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: High-titer anti-influenza plasma; Assigned to Arm(s): High-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: Low-titer anti-influenza plasma; Assigned to Arm(s): Low-titer anti-influenza plasma
D: Intervention Type: BIOLOGICAL; Name: COVID-19 convalescent plasma; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Brief Summary: This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.


Options:
A: Arm Label: COVID-19 patients treated with convalescent plasma; Type: EXPERIMENTAL; Interventions: Biological: Convalescent Plasma | Intervention Type: BIOLOGICAL; Name: Convalescent Plasma; Assigned to Arm(s): COVID-19 patients treated with convalescent plasma
B: Arm Label: High-titer anti-influenza plasma; Type: EXPERIMENTAL; Interventions: Biological: High-titer anti-influenza plasma | Arm Label: Low-titer anti-influenza plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Low-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: High-titer anti-influenza plasma; Assigned to Arm(s): High-titer anti-influenza plasma | Intervention Type: BIOLOGICAL; Name: Low-titer anti-influenza plasma; Assigned to Arm(s): Low-titer anti-influenza plasma
C: Arm Label: treated; Type: EXPERIMENTAL; Interventions: Other: hyperimmune plasma | Intervention Type: OTHER; Name: hyperimmune plasma; Assigned to Arm(s): treated
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IVIG dose: 0.15 g/kg; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 antibody based IVIG therapy | Arm Label: IVIG dose: 0.20 g/kg; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 antibody based IVIG therapy | Arm Label: IVIG dose: 0.25 g/kg; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 antibody based IVIG therapy | Arm Label: IVIG dose: 0.30 g/kg; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 antibody based IVIG therapy | Intervention Type: BIOLOGICAL; Name: SARS-CoV-2 antibody based IVIG therapy; Assigned to Arm(s): IVIG dose: 0.15 g/kg, IVIG dose: 0.20 g/kg, IVIG dose: 0.25 g/kg, IVIG dose: 0.30 g/kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recurrent Urinary Tract Infection Prevention With Biologic Cranberry Extract Intake Standardized in Proanthocyanidins: A Double-blind Clinical Trial
Brief Summary: The purpose of this clinical trial study is to assess, among young and sexually active women presenting recurrent urinary tract infection (UTIs), efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mg/day of Proanthocyanidins (PACs), compared to a control dose quantified and standardized to 2 mg/day of PACs on mean number of new UTIs during a 6-month follow-up period.


Options:
A: Arm Label: cranberry juice; Type: ACTIVE_COMPARATOR; Interventions: Other: cranberry juice | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo beverage | Intervention Type: OTHER; Name: cranberry juice; Assigned to Arm(s): cranberry juice | Intervention Type: OTHER; Name: placebo beverage; Assigned to Arm(s): Placebo
B: Arm Label: Optimal dose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Arm Label: Control dose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry extract; Assigned to Arm(s): Control dose, Optimal dose
C: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Recurrent Urinary Tract Infection Prevention With Biologic Cranberry Extract Intake Standardized in Proanthocyanidins: A Double-blind Clinical Trial
Brief Summary: The purpose of this clinical trial study is to assess, among young and sexually active women presenting recurrent urinary tract infection (UTIs), efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mg/day of Proanthocyanidins (PACs), compared to a control dose quantified and standardized to 2 mg/day of PACs on mean number of new UTIs during a 6-month follow-up period.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Intervention Type: DRUG; Name: Cranberry juice cocktail; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4
B: Arm Label: Optimal dose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Arm Label: Control dose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry extract; Assigned to Arm(s): Control dose, Optimal dose
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Novel Healthcare-Community Partnership for Childhood Obesity Treatment: A Randomized Pilot Study
Brief Summary: The primary aim of this study is to reduce body mass index (BMI) among children ages 5-11 who are obese by integrating behavioral treatment strategies in both clinic (Healthy Lifestyles) and community (Bull City Fit) settings. A two-group randomized, controlled, non-blinded pilot design will be utilized. The intended target population is the adult caregiver and a child with obesity (BMI ≥ 95th percentile) aged 5-11. The intervention condition will be standard care with Healthy Lifestyles programming plus Bull City Fit; upcoming activities will be texted to the parents mobile device using GoogleVoice. The control condition will be standard clinical care with Healthy Lifestyles programming. Primary outcome is BMI at 6 months. Secondary outcomes include anthropometric, psychosocial, and reported health behaviors.


Options:
A: Arm Label: Community-eùbedded reproductive health interventions; Type: EXPERIMENTAL; Interventions: Behavioral: Theory of planned behaviour (TPB) and social cognitive theory (SCT). | Arm Label: Community members without intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Theory of planned behaviour (TPB) and social cognitive theory (SCT).; Assigned to Arm(s): Community-eùbedded reproductive health interventions
B: Arm Label: Education-only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Lifestyles Clinic | Arm Label: Bull City Fit Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Bull City Healthy and Fit | Intervention Type: BEHAVIORAL; Name: Bull City Healthy and Fit; Assigned to Arm(s): Bull City Fit Intervention | Intervention Type: BEHAVIORAL; Name: Healthy Lifestyles Clinic; Assigned to Arm(s): Education-only
C: Arm Label: Multifaceted Strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted Strategy | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted Strategy; Assigned to Arm(s): Multifaceted Strategy
D: Arm Label: All Nations Breath of Life (ANBL); Type: EXPERIMENTAL; Interventions: Behavioral: All Nations Breath of Life (ANBL), Drug: Pharmacotherapy | Arm Label: Nontailored (NT); Type: EXPERIMENTAL; Interventions: Behavioral: Nontailored program (NT), Drug: Pharmacotherapy | Intervention Type: BEHAVIORAL; Name: All Nations Breath of Life (ANBL); Assigned to Arm(s): All Nations Breath of Life (ANBL) | Intervention Type: BEHAVIORAL; Name: Nontailored program (NT); Assigned to Arm(s): Nontailored (NT) | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): All Nations Breath of Life (ANBL), Nontailored (NT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Basel Incidence, Patient Characteristics, Outcome and Possible Strategies to Improve Outcome of Perioperative Myocardial Injury After Non-cardiac Surgery: 1-Year Follow-up
Brief Summary: This observational study includes patients undergoing major non-cardiac surgery, and screens them for the occurrence of perioperative myocardial injuries (PMI). Incidence, patient characteristics, pathophysiology, potential prevention and therapy strategies and 1-year outcomes of PMI will be described.


Options:
A: Arm Label: patients with hip fracture; Type: N/A; Interventions: Other: observation | Intervention Type: OTHER; Name: observation; Assigned to Arm(s): patients with hip fracture
B: N/A
C: N/A
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma
Brief Summary: This study evaluates the potential synergic anti-myeloma activity of clarithromycin when combined with VCD induction therapy in patients with newly diagnosed multiple myeloma.


Options:
A: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Drug: VCD induction therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: VCD induction therapy | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VCD induction therapy; Assigned to Arm(s): Clarithromycin, Placebo
B: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: clarithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clarithromycin | Intervention Type: DRUG; Name: clarithromycin; Assigned to Arm(s): Clarithromycin, Placebo
D: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Intensive Chemotherapy
Brief Summary: The purpose of this randomized trial will evaluate whether providing clinicians with daily reports from a well-validated, standardized, patient-centered electronic symptom survey tool (PRO-CTCAE) improves symptom burden in patients undergoing high-dose chemotherapy. Adult inpatients at UNC undergoing high-dose chemotherapy for preparative chemotherapy prior to stem cell infusion. Participants will be randomized into one of two arms: (1) a control arm with standard of care daily clinician interviews or (2) standard of care plus daily electronic symptom surveys, the results of which will be sent to clinicians electronically.


Options:
A: Arm Label: Electronic Symptom Survey; Type: EXPERIMENTAL; Interventions: Other: Electronic symptom survey | Arm Label: Blinded Electronic Symptom Survey; Type: ACTIVE_COMPARATOR; Interventions: Other: Blinded Electronic Symptom Survey | Intervention Type: OTHER; Name: Electronic symptom survey; Assigned to Arm(s): Electronic Symptom Survey | Intervention Type: OTHER; Name: Blinded Electronic Symptom Survey; Assigned to Arm(s): Blinded Electronic Symptom Survey
B: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: THRIVE App; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: THRIVE App | Arm Label: THRIVE App+Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: THRIVE App, Behavioral: Tailored Feedback Messages | Intervention Type: BEHAVIORAL; Name: THRIVE App; Assigned to Arm(s): THRIVE App, THRIVE App+Feedback | Intervention Type: BEHAVIORAL; Name: Tailored Feedback Messages; Assigned to Arm(s): THRIVE App+Feedback
C: Arm Label: Implementation intervention; Type: EXPERIMENTAL; Interventions: Other: Implementation intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation intervention; Assigned to Arm(s): Implementation intervention
D: Arm Label: PHR Group; Type: ACTIVE_COMPARATOR; Interventions: Other: SANOIA Website | Arm Label: Non-PHR Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: SANOIA Website; Assigned to Arm(s): PHR Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nicotine Delivery From Novel Non-tobacco Electronic Systems (ENDS)
Brief Summary: This randomized pilot clinical trial studies nicotine delivery from novel non-tobacco electronic system (ENDS) in smokers. Studying the levels of nicotine delivered by various types and brands of ENDS to the bloodstream, and comparing this to the levels delivered from conventional cigarettes (the participant's own brand) may help provide information about the use of nicotine-containing products that may help inform/reform current tobacco policy, practice, and harm reduction approaches.


Options:
A: Arm Label: Arm I (different type of ENDS product at each visit); Type: EXPERIMENTAL; Interventions: Other: Electronic Cigarette, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Questionnaire Administration | Arm Label: Arm II (BLU e-cigarette ENDS product with different flavors); Type: EXPERIMENTAL; Interventions: Other: Electronic Cigarette, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Questionnaire Administration | Intervention Type: OTHER; Name: Electronic Cigarette; Assigned to Arm(s): Arm I (different type of ENDS product at each visit) | Intervention Type: OTHER; Name: Electronic Cigarette; Assigned to Arm(s): Arm II (BLU e-cigarette ENDS product with different flavors) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (different type of ENDS product at each visit), Arm II (BLU e-cigarette ENDS product with different flavors) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (different type of ENDS product at each visit), Arm II (BLU e-cigarette ENDS product with different flavors) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (different type of ENDS product at each visit), Arm II (BLU e-cigarette ENDS product with different flavors)
B: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
C: Arm Label: Electronic cigarettes; Type: EXPERIMENTAL; Interventions: Other: disposable electronic cigarettes | Intervention Type: OTHER; Name: disposable electronic cigarettes; Assigned to Arm(s): Electronic cigarettes
D: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cardiac Rehabilitation on Functional Capacity and Cardiovascular Risk Factors in Brazilian Patients Assisted by Public Health Care: A Randomized Controlled Trial
Brief Summary: The purpose of this trial are to pragmatically investigate whether participation in a comprehensive CR (i.e., exercise with education) program in a Latin American MIC results in better functional capacity, cardiovascular risk factor control, health behavior, disease-related knowledge, depressive symptoms and lower mortality when compared exercise only CR or wait list control.


Options:
A: Arm Label: Baduanjin exercise group; Type: EXPERIMENTAL; Interventions: Other: Baduanjin exercise | Arm Label: usual exercise control group; Type: ACTIVE_COMPARATOR; Interventions: Other: aerobic exercise | Intervention Type: OTHER; Name: Baduanjin exercise; Assigned to Arm(s): Baduanjin exercise group | Intervention Type: OTHER; Name: aerobic exercise; Assigned to Arm(s): usual exercise control group
B: Arm Label: comprehensive CR; Type: EXPERIMENTAL; Interventions: Behavioral: comprehensive CR | Arm Label: exercise-based CR; Type: ACTIVE_COMPARATOR; Interventions: Other: exercise-based CR | Arm Label: wait list control; Type: OTHER; Interventions: Other: wait list control | Intervention Type: BEHAVIORAL; Name: comprehensive CR; Assigned to Arm(s): comprehensive CR | Intervention Type: OTHER; Name: exercise-based CR; Assigned to Arm(s): exercise-based CR | Intervention Type: OTHER; Name: wait list control; Assigned to Arm(s): wait list control
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care + letters; Type: EXPERIMENTAL; Interventions: Behavioral: Usual care + letters | Arm Label: Usual care + letters + automated calls; Type: EXPERIMENTAL; Interventions: Behavioral: Usual care + letters + automated calls | Intervention Type: BEHAVIORAL; Name: Usual care + letters; Assigned to Arm(s): Usual care + letters | Intervention Type: BEHAVIORAL; Name: Usual care + letters + automated calls; Assigned to Arm(s): Usual care + letters + automated calls
D: Arm Label: Comprehensive phase one rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Comprehensive phase one rehabilitation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive phase one rehabilitation; Assigned to Arm(s): Comprehensive phase one rehabilitation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1/2, Dose-Escalation, Safety, Tolerability and Efficacy Study of Valoctocogene Roxaparvovec, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A
Brief Summary: This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy vector in participants with severe haemophilia A.


Options:
A: Arm Label: Group 1; Type: OTHER; Interventions: Genetic: Gene Transfer, Drug: scAAV2/8-LP1-hFIXco | Intervention Type: GENETIC; Name: Gene Transfer; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: scAAV2/8-LP1-hFIXco; Assigned to Arm(s): Group 1
B: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, Biological: PEGylated Recombinant Factor VIII | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: PEGylated Recombinant Factor VIII | Intervention Type: BIOLOGICAL; Name: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): Prophylaxis | Intervention Type: BIOLOGICAL; Name: PEGylated Recombinant Factor VIII; Assigned to Arm(s): On-demand
C: Arm Label: valoctocogene roxaparvovec; Type: EXPERIMENTAL; Interventions: Biological: valoctocogene roxaparvovec | Intervention Type: BIOLOGICAL; Name: valoctocogene roxaparvovec; Assigned to Arm(s): valoctocogene roxaparvovec
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Genetic: AAV5-hFIX | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Genetic: AAV5-hFIX | Intervention Type: GENETIC; Name: AAV5-hFIX; Assigned to Arm(s): Cohort 1, Cohort 2

Answer: C